CYTK Cytokinetics, Incorporated

NASDAQ
$61.35

Cytokinetics, Incorporated (CYTK) Institutional Ownership

What the institutions did with CYTK last quarter, from their 13F filings. Counting managers rather than shares is the point: a single index fund adding to a position tells you far less than four hundred separate managers all deciding to. Positions as reported for the quarter ended September 30, 2026.

Managers compared
3
filed both this quarter and last
Managers holding
2
-1 on the quarter
Buyers
1
0 opened new
Sellers
2
1 sold out entirely
Buyer share
33.3%
of managers who traded it
Breadth
-33.3
net buyers, as a share of those trading

Only 3 managers reported a position this quarter, so the percentages above describe a very small sample.

Every manager below opens. Subscribers can see any firm's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.

Sign in or subscribe

Largest holders

Manager Shares % of reported
MassMutual Private Wealth & Trust, FSB 376 76.7%
Versant Capital Management, Inc 114 23.3%

Largest changes

Manager Action Previous Current Change
MassMutual Private Wealth & Trust, FSB Reduced 448 376 -72
Versant Capital Management, Inc Increased 86 114 +28
EASTERN BANK Sold Out 10 0 -10

13F filings are due 45 days after quarter end and cover long positions in U.S.-listed equities only, so this is a lagged and partial picture: shorts, bonds and foreign listings never appear. Options positions are excluded here rather than folded into the share counts. Political ownership is coming.